Oxagen Limited is a privately-held biopharmaceutical company which has licensed rights to an experimental medicine called OC000459 as follows:

- for the Russian and CIS markets to Eleventa LLC, part of the Russian biotech holding company OOO Maxwell Biotech Group.

- the rights to exploit OC000459 and back-up molecules worldwide excluding Russia and CIS, were assigned by Oxagen to Atopix Therapeutics Limited in October 2012.

OC000459 is a once-daily oral CRTH2 antagonist which has demonstrated encouraging activity in the treatment of eosinophilic asthma and allergic rhinoconjunctivitis, and an excellent safety profile.